RxDoctor Payments Data

Margaret Davenport, DO

Internal Medicine · Anniston, ALNPI 1164435806

Payments from drug & device makers

$1,008in general payments, 2019–2025

Across 41 payments — averaging $24.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$436
  • Novo Nordisk$155
  • AbbVie$132
  • Bayer$79
  • Merck$72
  • AstraZeneca$62
  • plus $71 from 3 others

What the payments were for

  • Food & beverage$1,008100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim25$436
Novo Nordisk5$155
AbbVie(2 entities)4$132
Bayer1$79
Merck1$72
AstraZeneca1$62
Lilly USA, LLC2$26
Pfizer1$25
Exact Sciences1$20

How this compares

$1,008 in reported general payments places this provider in the 60th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$65,504
Medicare patients
92
Services billed
1,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$33,190
JardianceEmpagliflozin23$21,048
LinzessLinaclotide17$13,346
Rosuvastatin Calcium73$1,313
Ipratropium Bromide37$1,101
Omeprazole70$1,036
Valsartan31$806
Levothyroxine Sodium56$730
Famotidine40$582
Atorvastatin Calcium57$575
Pantoprazole Sodium32$562
Mirtazapine15$500
Estradiol12$496
Duloxetine Hcl11$431
Potassium Chloride28$411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$33,19044 claims
Boehringer IngelheimJardiance$436$21,04823 claims
AbbVieLinzess$132$13,34617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Anniston

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →